These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36806966)

  • 1. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
    Ramnaraign B; Sartor O
    Oncologist; 2023 May; 28(5):392-401. PubMed ID: 36806966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
    Shah H; Ravi P; Sonpavde G; Jacene H
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1163-1175. PubMed ID: 36305305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
    Keam SJ
    Mol Diagn Ther; 2022 Jul; 26(4):467-475. PubMed ID: 35553387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
    Fallah J; Agrawal S; Gittleman H; Fiero MH; Subramaniam S; John C; Chen W; Ricks TK; Niu G; Fotenos A; Wang M; Chiang K; Pierce WF; Suzman DL; Tang S; Pazdur R; Amiri-Kordestani L; Ibrahim A; Kluetz PG
    Clin Cancer Res; 2023 May; 29(9):1651-1657. PubMed ID: 36469000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Rahbar K; Essler M; Eiber M; la Fougère C; Prasad V; Fendler WP; Rassek P; Hasa E; Dittmann H; Bundschuh RA; Pabst KM; Kurtinecz M; Schmall A; Verholen F; Sartor O
    J Nucl Med; 2023 Dec; 64(12):1925-1931. PubMed ID: 37827838
    [No Abstract]   [Full Text] [Related]  

  • 7. Lutetium-177-PSMA-617: A Vision of the Future.
    Chandran E; Figg WD; Madan R
    Cancer Biol Ther; 2022 Dec; 23(1):186-190. PubMed ID: 35220877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
    Liu X; Fang GC; Lu H; Shi ZD; Chen ZS; Han CH
    Drugs Today (Barc); 2023 Jan; 59(1):37-49. PubMed ID: 36811416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 10. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
    Parveen A; Fatima A; Fatima I; Khan IU; Shahid A
    Nucl Med Commun; 2023 Oct; 44(10):876-887. PubMed ID: 37440195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of radium-223 and the pharmacy preparation
    Quist SW; Paulissen JHJ; Wyndaele DNJ; Nagarajah J; Freriks RD
    J Med Econ; 2023; 26(1):366-375. PubMed ID: 36905581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
    Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH
    Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.
    Muniz M; Loprinzi CL; Orme JJ; Koch RM; Mahmoud AM; Kase AM; Riaz IB; Andrews JR; Thorpe MP; Johnson GB; Kendi AT; Kwon ED; Nauseef JT; Morgans AK; Sartor O; Childs DS
    Cancer Treat Rev; 2024 Jun; 127():102748. PubMed ID: 38703593
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Chi KN; Yip SM; Bauman G; Probst S; Emmenegger U; Kollmannsberger CK; Martineau P; Niazi T; Pouliot F; Rendon R; Hotte SJ; Laidley DT; Saad F
    Curr Oncol; 2024 Mar; 31(3):1400-1415. PubMed ID: 38534939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
    J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.